Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.

Zanwar, Saurabh; Ho, Matthew; Buadi, Francis K.; Ailawadhi, Sikander; Larsen, Jeremy; Bergsagel, Leif; Binder, Moritz; Chanan-Khan, Asher; Dingli, David; Dispenzieri, Angela; Fonseca, Rafael; Gertz, Morie A.; Gonsalves, Wilson; Go, Ronald S.; Hayman, Suzanne; Kapoor, Prashant; Kourelis, Taxiarchis; Lacy, Martha Q.; Leung, Nelson; Lin, Yi

Of the 42 patients with MM/AL, 25 patients were in remission and 1 out of these 25 (4%) patients developed a 2nd COVID-19 infection. Notably, all severe 2nd COVID-19 infections occurred in patients that were unvaccinated at the time of the second infection, and this should serve as a reaffirmation of the importance of vaccination even in patients with a prior COVID-19 infection. Out of 19,943 patients with an underlying monoclonal gammopathy, 483 patients (2.4%) had a documented positive COVID-19 PCR test and 101 patients had COVID-19 antibody testing performed [spike Ab = 54, nucleocapsid Ab = 47] (Supplementary Fig. While inferior immune response to COVID-19 vaccination have been described in patients with monoclonal gammopathies [[8]], information on the rate and severity of COVID-19 infections in patients who do demonstrate immunogenicity post infection or vaccination is limited.

MONOCLONAL gammopathies; COVID-19; PLASMA cell diseases

Blood Cancer Journal, 2022, Vol 12, Issue 11, p1

2044-5385

Academic Journal

10.1038/s41408-022-00752-z